CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that its abstract, “CRx-102, a dissociated glucocorticoid (GC), and prednisolone provide safe and effective pain relief in knee osteoarthritis (OA) in a placebo-controlled Phase 2 trial (COMET-1)”, has been accepted for oral presentation at EULAR 2009, the Annual European Congress of Rheumatology in Copenhagen on June 12, 2009. The abstract can be accessed online at www.eular.org: click on "EULAR Congress 2009” and “abstracts", and enter the search term or abstract number. The abstract will also be published in the congress abstract book, a supplement to “Annals of Rheumatic Diseases - the EULAR Journal”.
